Sawtooth Solutions, LLC Vertex Pharmaceuticals Inc Transaction History

Sawtooth Solutions, LLC

$3.64 Billion
Q4 2023

A detailed history of Sawtooth Solutions, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sawtooth Solutions, LLC holds 22,783 shares of VRTX stock, worth $9.36 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

22,783

Previous 18,452 23.47%

Holding current value

$9.36 Million

Previous $6.42 Million 44.48%

% of portfolio

0.25%

Previous 0.21%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	BUY	$343.0 - $410.68 $1.49 Million - $1.78 Million	4,331 Added 23.47%	22,783 $9.27 Million
Q3 2023 Oct 19, 2023	SELL	$338.18 - $362.46 $4,058 - $4,349	-12 Reduced 0.06%	18,452 $6.42 Million
Q2 2023 Jul 26, 2023	BUY	$314.42 - $351.91 $2.88 Million - $3.23 Million	9,171 Added 98.69%	18,464 $6.5 Million
Q1 2023 Apr 27, 2023	BUY	$283.23 - $323.1 $1.46 Million - $1.67 Million	5,167 Added 125.23%	9,293 $2.93 Million
Q4 2022 Feb 02, 2023	SELL	$285.76 - $321.48 $72,868 - $81,977	-255 Reduced 5.82%	4,126 $1.19 Million
Q3 2022 Oct 12, 2022	BUY	$273.83 - $305.53 $134,176 - $149,709	490 Added 12.59%	4,381 $1.27 Million
Q2 2022 Jul 19, 2022	BUY	$234.96 - $292.55 $107,376 - $133,695	457 Added 13.31%	3,891 $1.1 Million
Q1 2022 May 20, 2022	BUY	$221.42 - $260.97 $255,075 - $300,637	1,152 Added 50.48%	3,434 $897,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $403,936 - $509,912	2,282 New	2,282 $502,000
Q3 2020 Nov 04, 2020	SELL	$255.65 - $303.1 $417,220 - $494,659	-1,632 Closed	0 $0
Q2 2020 Aug 06, 2020	BUY	$225.48 - $295.8 $367,983 - $482,745	1,632 New	1,632 $474,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sawtooth Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sawtooth Solutions, LLC with notifications on news.

Account

Sawtooth Solutions, LLC Vertex Pharmaceuticals Inc Transaction History